研究者詳細 - 武市　拓也

論文 - 武市　拓也

分割表示 227 件中 1 - 20 件目／全件表示 >>

Expanding the Relevance of Anti-Ki/SL beyond SLE to Systemic Sclerosis and Dermatomyositis in In-house ELISA Analyses. 査読有り国際誌

Koizumi H, Muro Y, Yamashita Y, Ogawa-Momohara M, Kamiya S, Akashi N, Noda E, Takeichi T, Akiyama M

Clinical and experimental dermatology 2025年4月

A Case of DPP-4 Inhibitor-Associated Bullous Pemphigoid With Anti-LAD-1 IgG Antibodies Arising From a Post-Traumatic Scar. 査読有り国際誌

Sasamoto M, Ogawa-Momohara M, Ishii N, Takeichi T, Muro Y, Akiyama M

International journal of dermatology 2025年4月

Estimating the proportions of allele frequencies for SERPINA12 pathogenic variants in Japanese patients with Nagashima-type palmoplantar keratosis/keratoderma. 査読有り国際誌

Ebata A, Takeichi T, Nishida K, Chretien B, Miyazaki A, Yoshikawa T, Suzuki Y, Tanahashi K, Fukaura R, Seishima M, Suga Y, Muro Y, Nakazawa Y, Ogi T, Akiyama M

The British journal of dermatology 2025年3月

Occurrence of bullous pemphigoid during long-term maintenance treatment for pemphigus vulgaris in remission 査読有り国際誌

Goto, A; Takeichi, T; Ishii, N; Yamashita, Y; Ogawa-Momohara, M; Muro, Y; Akiyama, M

JOURNAL OF DERMATOLOGY 2025年3月

Cutaneous inflammation with upregulated interleukin-36γ and TNFα in a patient with loricrin keratoderma 査読有り

Maki, T; Murakami, M; Takeichi, T; Noda, T; Tanahashi, K; Mitsuma, T; Muro, Y; Akiyama, M

JOURNAL OF DERMATOLOGY 2025年3月

Alopecia universalis and type 1 diabetes mellitus both successfully controlled with baricitinib in a patient with autoimmune polyglandular syndrome type 3A 査読有り国際誌

Goto, A; Yamashita, Y; Yuasa, J; Kamiya, S; Akashi, N; Koizumi, H; Ogawa-Momohara, M; Takeichi, T; Muro, Y; Akiyama, M

JOURNAL OF DERMATOLOGY 2025年3月

Dupilumab treatment decreases expression of microRNAs related to B cell activation in peripheral blood mononuclear cells of atopic dermatitis patients. 査読有り国際誌

Matsui K, Ogawa-Momohara M, Yokoi A, Takeichi T, Yoshida K, Kitagawa M, Taki T, Murase C, Muro Y, Akiyama M

Journal of dermatological science 2025年2月

Expanding the SLURP1 disease spectrum: From mal de Meleda to palmoplantar keratoderma/progressive symmetric erythrokeratoderma. 招待有り査読有り国際共著国際誌

Takeichi T, Hsu CK

The British journal of dermatology 2025年2月

Concurrent wild-type transthyretin amyloidosis and psoriasis vulgaris in an elderly man 査読有り国際誌

Fujii, Y; Takeichi, T; Yamashita, Y; Okumura, T; Sakakibara, A; Muro, Y; Akiyama, M

JOURNAL OF DERMATOLOGY 2025年2月

Nonsense Variant in CYP4F22 Causes Malformation of Corneocyte Lipid Envelopes in a Lamellar Ichthyosis Patient. 査読有り国際誌

Fukaura R, Tanahashi K, Omi M, Takeichi T, Akiyama M

Acta dermato-venereologica 105 巻頁： adv41072 2025年2月

Hyperactivation of the IL-17 Axis and IL-36 Signaling in<i> Card14-</i> Mutant Pityriasis Rubra Pilaris Mouse Model 査読有り国際誌

Yoshikawa, T; Takeichi, T; Hirabayashi, T; Muro, Y; Miyasaka, Y; Ohno, T; Akiyama, M

JOURNAL OF INVESTIGATIVE DERMATOLOGY 145 巻 ( 2 ) 頁： 427 - 432 2025年2月

Selumetinib for symptomatic, inoperable plexiform neurofibromas in pediatric patients with neurofibromatosis type 1: the first single-center real-world case series in Japan 査読有り国際誌

Nishida, Y; Nonobe, N; Kidokoro, H; Kato, T; Takeichi, T; Ikuta, K; Urakawa, H; Sakai, T; Koike, H; Fujito, T; Imagama, S

JAPANESE JOURNAL OF CLINICAL ONCOLOGY 2025年1月

Anti-SS-B antibody seroconversion occurring simultaneously with exacerbation of pulmonary arterial hypertension in a patient with primary Sjögren's syndrome in long-term remission 査読有り国際誌

Marina, EN; Ogawa-Momohara; Nakano, Y; Yamashita, Y; Akashi, N; Kamiya, S; Koizumi, H; Takeichi, T; Muro, Y; Akiyama, M

EUROPEAN JOURNAL OF DERMATOLOGY 35 巻 ( 1 ) 頁： 61 - 63 2025年1月

Predictive Value of Anti-SMN Complex Antibodies for Monitoring Cardiopulmonary Complications in MCTD: Insights From an ELISA Study Using Recombinant Gemin4 and an Anti-Nuclear Antibody Test. 査読有り国際誌

Haruka Koizumi, Yoshinao Muro, Satoshi Kamiya, Norika Akashi, Yuta Yamashita, Mariko Ogawa-Momohara, Takuya Takeichi, Masashi Akiyama

International journal of rheumatic diseases 28 巻 ( 1 ) 頁： e70089 2025年1月

Generalized acrodermatitis continua of Hallopeau with an <i>IL36RN</i> variant successfully treated with bimekizumab 査読有り国際誌

Yoshikawa, T; Takeichi, T; Fukaura, R; Ikeya, S; Akiyama, M

JOURNAL OF DERMATOLOGY 51 巻 ( 12 ) 頁： e449 - e451 2024年12月

【すぐに役立つ　すごく役立つ　皮膚科検査の基本マニュアル】遺伝学的検査・細胞解析　角化異常症(魚鱗癬)における遺伝子異常とその診断

後藤文音, 武市拓也

皮膚病診療 2024年12月

【乾癬再考-治療の前に-】(Part1.)乾癬様病態　(総説3)乾癬・乾癬類縁疾患と関連遺伝子のバリアント

野口晴香, 武市拓也

Visual Dermatology 2024年12月

Improvement of Skin Lesions in an Adult with CHILD Syndrome Treated with 2% Ketoconazole Cream 査読有り国際誌

Michiya O., Tanahasi K., Takeichi T., Akiyama M.

Acta dermato-venereologica 104 巻 2024年11月

Measurement of clinical outcomes of Netherton syndrome following treatment with upadacitinib 査読有り国際誌

Murase, C; Fukaura, R; Yamada, N; Konishi-Izuchi, N; Adachi, H; Taki, T; Hara, S; Takeichi, T; Akiyama, M

JOURNAL OF DERMATOLOGY 51 巻 ( 11 ) 頁： e399 - e401 2024年11月

Biomarkers and patient-related factors associated with clinical outcomes in dupilumab-treated atopic dermatitis. 査読有り国際誌

Kido-Nakahara M, Onozuka D, Izuhara K, Saeki H, Nunomura S, Takenaka M, Matsumoto M, Kataoka Y, Fujimoto R, Kaneko S, Morita E, Tanaka A, Hide M, Okano T, Miyagaki T, Aoki N, Nakajima K, Ichiyama S, Tonomura K, Nakagawa Y, Tamagawa-Mineoka R, Masuda K, Takeichi T, Akiyama M, Ishiuji Y, Katsuta M, Kinoshita Y, Tateishi C, Yamamoto A, Morita A, Matsuda-Hirose H, Hatano Y, Kawasaki H, Tanese K, Ohtsuki M, Kamiya K, Kabata Y, Abe R, Mitsui H, Kawamura T, Tsuji G, Furue M, Katoh N, Nakahara T

The journal of allergy and clinical immunology. Global 3 巻 ( 4 ) 頁： 100317 - 100317 2024年11月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Journal of Allergy and Clinical Immunology: Global

Background: Atopic dermatitis (AD) is a common chronic eczematous skin disease with severe pruritus. Several new therapeutic agents for AD such as dupilumab, an anti–IL-4Rα antibody, have been developed in recent years. We need to predict which agent is the best choice for each patient, but this remains difficult. Objective: Our aim was to examine clinical background factors and baseline biomarkers that could predict the achievement of improved clinical outcomes in patients with AD treated with dupilumab. Methods: A multicenter, prospective observational study was conducted on 110 patients with AD. The Eczema Area and Severity Index was used as an objective assessment, and the Patient-Oriented Eczema Measure and Numerical Rating Scale for Pruritus were used as patient-reported outcomes. In addition, some clinical background factors were evaluated. Results: The achievement of an absolute Eczema Area and Severity Index of 7 or less was negatively associated with current comorbidity of food allergy and baseline serum lactate dehydrogenase (LDH) levels. There were negative associations between achievement of a Patient-Oriented Eczema Measure score of 7 or less and duration of severe AD and between achievement of an itching Numerical Rating Scale for Pruritus score of 1 or less and current comorbidity of allergic conjunctivitis or baseline serum periostin level. Furthermore, signal detection analysis showed that a baseline serum LDH level less than 328 U/L could potentially be used as a cutoff value for predicting the efficacy of dupilumab. Conclusion: Baseline biomarkers such as LDH and periostin and clinical background factors such as current comorbidity of food allergy and a long period of severe disease may be useful indicators when choosing dupilumab for systemic treatment for AD, as they can predict the efficacy of dupilumab.

DOI： 10.1016/j.jacig.2024.100317

Scopus

PubMed

　前のページ - 次のページ　

<武市 拓也>

論文 - 武市 拓也

<武市　拓也>

論文 - 武市　拓也